CVA Family Office LLC Buys 311 Shares of Humana Inc. (NYSE:HUM)

CVA Family Office LLC grew its stake in Humana Inc. (NYSE:HUM) by 586.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 364 shares of the insurance provider’s stock after acquiring an additional 311 shares during the period. CVA Family Office LLC’s holdings in Humana were worth $136,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of HUM. International Assets Investment Management LLC increased its position in Humana by 32,648.4% during the 4th quarter. International Assets Investment Management LLC now owns 134,596 shares of the insurance provider’s stock valued at $61,619,000 after purchasing an additional 134,185 shares during the period. Prime Capital Investment Advisors LLC lifted its holdings in Humana by 36.6% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 1,130 shares of the insurance provider’s stock worth $517,000 after buying an additional 303 shares during the period. Stratos Wealth Partners LTD. boosted its position in Humana by 21.3% during the 4th quarter. Stratos Wealth Partners LTD. now owns 1,570 shares of the insurance provider’s stock valued at $719,000 after acquiring an additional 276 shares in the last quarter. 180 Wealth Advisors LLC increased its holdings in shares of Humana by 9.9% in the 4th quarter. 180 Wealth Advisors LLC now owns 946 shares of the insurance provider’s stock valued at $444,000 after acquiring an additional 85 shares during the period. Finally, Equitable Trust Co. bought a new position in shares of Humana in the 4th quarter worth $650,000. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of Humana stock traded down $9.69 during trading hours on Wednesday, reaching $345.56. The stock had a trading volume of 912,936 shares, compared to its average volume of 1,734,798. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $530.54. The company has a current ratio of 1.66, a quick ratio of 1.67 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $41.64 billion, a PE ratio of 21.52, a PEG ratio of 2.09 and a beta of 0.51. The stock’s 50 day moving average is $368.17 and its 200 day moving average is $347.32.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter last year, the business earned $8.94 earnings per share. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Equities analysts expect that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Robert W. Baird started coverage on shares of Humana in a report on Thursday, May 30th. They issued a “neutral” rating and a $374.00 target price for the company. Morgan Stanley began coverage on Humana in a report on Monday, June 24th. They set an “equal weight” rating and a $374.00 price objective for the company. Oppenheimer upped their target price on Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Royal Bank of Canada dropped their price target on Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. Finally, TD Cowen lifted their target price on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Fourteen research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus price target of $403.55.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.